Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease

SLN360 is a liver-targeted N-acetyl galactosamine (GalNAc)-conjugated small interfering RNA (siRNA) with a promising profile for addressing lipoprotein (a)-related cardiovascular risk. Here, we describe the findings from key preclinical safety studies. In vitro, SLN360 specifically reduced LPA expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Rider, David, Chivers, Simon, Aretz, Julia, Eisermann, Mona, Löffler, Kathrin, Hauptmann, Judith, Morrison, Eliot, Campion, Giles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Emerging Technologies, Methods, and Models
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516055/
https://www.ncbi.nlm.nih.gov/pubmed/35737426
http://dx.doi.org/10.1093/toxsci/kfac067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9516055/
https://www.ncbi.nlm.nih.gov/pubmed/35737426
http://dx.doi.org/10.1093/toxsci/kfac067

Ejemplares similares